<DOC>
	<DOCNO>NCT02537249</DOCNO>
	<brief_summary>Dexmedetomidine selective Î±2 adrenergic agonist consider analgesic , anxiolytic , anti-stress effect . This randomized , double-blind placebo-controlled trial intraoperative dexmedetomidine improvement quality recovery analgesia surgery . Patients scheduled undergo video-assisted thoracoscopic surgery ( VATS ) enrol . Patients recruit date surgery complete Quality Recovery-40 ( QoR-40 ) questionnaire surgery 24 48 hour post op . They also complete clinically significant pain score oxygenation postanesthetic recovery unit ( PACU ) .</brief_summary>
	<brief_title>Effects Dexmedetomidine Quality Recovery Analgesia After Video-assisted Thoracoscopic Surgery</brief_title>
	<detailed_description />
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . The inclusion criterion include patient schedule videoassisted thoracoscopic surgery lung cancer 2 . Adults 20 year age providing informed consent . 3 . American Society Anesthesiologists ( ASA ) Physical class II , &amp; III patient 1. severe functional liver kidney disease 2. history chronic pain require opioid treatment 3. arrhythmia receive treatment antiarrythmic drug . 4. severe bradycardia ( HR &lt; 45 bpm ) AV block 5. pathologic esophageal lesion ( esophageal stricture varix ) 6. pregnancy 7. psychiatric/central nervous system disturbance would preclude completion QoR40 questionnaire 8 . History alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>dexmedetomidine</keyword>
	<keyword>quality recovery</keyword>
</DOC>